Population pharmacokinetic modelling of total and unbound flucloxacillin in non-critically ill patients to devise a rational continuous dosing regimen
With antibiotic drug pipelines rapidly drying up [1], we need to optimally use the available drugs to retain our antimicrobial armamentarium. [2] In Europe, flucloxacillin is one of the clinically important anti-staphylococcal penicillins. Flucloxacillin is widely used and recommended for penicillin-resistant methicillin-susceptible Staphylococcal aureus (MSSA) infections, such as bacteremia [3], infective endocarditis [4], skin and soft tissue infections. [5]
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: S. Wilkes, I. van Berlo, J. ten Oever, F. Jansman, R. ter Heine Source Type: research